Iason GmbH has continued its refinancing efforts with local banks based on an IBR
December 2013 — The shareholders of Iason GmbH have completed a restructuring of the company and its refinancing efforts with local banks based on an IBR.
The Iason group produces radiopharmaceuticals and supplies special laboratory products to the target group "nuclear medicine" and "laboratory medicine" providing innovative products with the highest quality standards. The company has customers from all over Europe.
Our role in the transaction
Oaklins' team in Austria assisted Iason with the preparation of the IBR (independent business review) and negotiations with local banks regarding refinancing possibilities.
Sprechen Sie mit dem Deal-Team
Thomas Jungreithmeir
Oaklins Austria
Relevante Transaktionen
Indigo Capital has acquired a minority stake in Vivason
Indigo Capital has acquired a minority stake in Vivason, a leading network of hearing care centers, to support the company’s growth and enable management to increase its ownership stake.
Weitere InformationenUKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Weitere InformationenMedicija has acquired Saulės Šeimos Medicinos Centras
Medicija has acquired a 100% stake in Saulės Šeimos Medicinos Centras.
Weitere Informationen